Page 1

PYC Therapeutics 26 February 2021 APPENDIX 4D AND INTERIM FINANCIAL STATEMENTS Announcement PYC Therapeutics , ( ASX : PYC ) ( ' PYC ' or ' the Company ' ) , a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases , submits the following Appendix 4D and 31 December 2021 Interim Financial Statements . This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics limited . For personal use only ENDS For further information , please contact : INVESTORS Deborah Elson / Matthew DeYoung Argot Partners deborah@argotpartners.com matthew@argotpartners.com MEDIA Leo Vartorella Argot Partners leo@argotpartners.com About PYC Therapeutics PYC Therapeutics ( ASX : PYC ) is a development - stage biotechnology company pioneering a new generation of RNA therapeutics that utilize Cell Penetrating Peptides ( CPPs ) , a revolutionary delivery technology designed to overcome the major challenges of current gene - based therapies . PYC believes its CPP technology provides safer , more effective access for a wide range of potent and precise drug cargoes to the highest value drug targets that exist inside cells . The Company is leveraging its leading - edge science to develop a pipeline of novel therapies with an initial focus on inherited eye diseases for which it has unveiled three preclinical stage assets . PYC's discovery and laboratory operations are located in Australia and the Company recently launched and expansion into the U.S. for its preclinical , clinical , regulatory and business development operations . For more information , visit pyctx.com , or follow us on LinkedIn and Twitter . +61 8 6151 0994 pyctx.com | ACN 098 391 961 1